
Immunome Inc (NASDAQ:IMNM) shares are trading higher by 19.44% at $3.39 after the company published data demonstrating its COVID-19 antibody cocktail IMM-BCP-01 cleared the omicron variant of SARS-CoV-2 when tested in vivo in hamsters.
When tested in hamster models, Immunome says IMM-BCP-01 retained full coverage against the Omicron variant. Specifically, Immunome said the data suggest strong activity of two antibodies in the cocktail, IMM20253 and IMM20184, which target distinct, non-overlapping epitopes of SARS-CoV-2, against the Omicron variant.